These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33315686)

  • 1. Immunotherapy approaches targeting neuroblastoma.
    Nguyen R; Thiele CJ
    Curr Opin Pediatr; 2021 Feb; 33(1):19-25. PubMed ID: 33315686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
    Peinemann F; van Dalen EC; Enk H; Tytgat GA
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies for Pediatric Solid Tumors: A Targeted Update.
    Gupta A; Cripe TP
    Paediatr Drugs; 2022 Jan; 24(1):1-12. PubMed ID: 34822115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of Neuroblastoma: Facts and Hopes.
    Anderson J; Majzner RG; Sondel PM
    Clin Cancer Res; 2022 Aug; 28(15):3196-3206. PubMed ID: 35435953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-based therapy for neuroblastoma.
    Cheung NK
    Curr Oncol Rep; 2000 Nov; 2(6):547-53. PubMed ID: 11122891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
    Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
    Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune therapies for neuroblastoma.
    Navid F; Armstrong M; Barfield RC
    Cancer Biol Ther; 2009 May; 8(10):874-82. PubMed ID: 19342881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
    Heczey A; Louis CU
    Discov Med; 2013 Dec; 16(90):287-94. PubMed ID: 24333408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
    Chan GC; Chan CM
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Children's Oncology Group's 2013 blueprint for research: neuroblastoma.
    Park JR; Bagatell R; London WB; Maris JM; Cohn SL; Mattay KK; Hogarty M;
    Pediatr Blood Cancer; 2013 Jun; 60(6):985-93. PubMed ID: 23255319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
    Castel V; Segura V; Cañete A
    Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
    Ploessl C; Pan A; Maples KT; Lowe DK
    Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.
    Louis CU; Brenner MK
    Curr Pharm Des; 2009; 15(4):424-9. PubMed ID: 19199969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.